For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development-Nonrelated Party | 2,975 | 5,741* | - | - |
| Research and development - related parties note 8-Related Party | 317 | 9* | - | - |
| Research and development | - | - | 5,320 | 6,707 |
| General and administrative-Nonrelated Party | 7,147 | 8,249* | - | - |
| General and administrative | - | - | 9,372 | 5,856 |
| General and administrative - related parties note 8-Related Party | 24 | 4* | - | - |
| Total operating expenses | 10,463 | 14,002* | 14,692 | 12,563 |
| Interest income | 297 | 376* | 554 | 192 |
| Interest expense note 6 | 274 | 245* | 192 | 191 |
| Change in fair value of contingent consideration note 4 and note 5 | -285 | 104* | 106 | 97 |
| Other (expenses) income | -13 | 60* | -5 | -59 |
| Total other income | 295 | 88* | 251 | -155 |
| Net loss | -10,168 | -13,914 | -14,441 | -12,718 |
| Net unrealized loss on marketable securities | -8 | - | 6 | -3 |
| Total other comprehensive loss | -8 | - | 6 | -3 |
| Comprehensive loss | -10,176 | - | -14,435 | -12,721 |
| Basic EPS | -0.19 | -0.309 | -0.28 | -0.37 |
| Diluted EPS | -0.19 | -0.309 | -0.28 | -0.37 |
| Basic Average Shares | 53,381,989 | 45,081,222 | 51,017,662 | 34,685,072 |
| Diluted Average Shares | 53,381,989 | 45,081,222 | 51,017,662 | 34,685,072 |
ACHIEVE LIFE SCIENCES, INC. (ACHV)
ACHIEVE LIFE SCIENCES, INC. (ACHV)